https://www.gov.uk/government/publications/sunbeds-safety-advice<\/a><\/p> <\/p>
The Department is considering whether current measures are effective for protecting sunbed users.<\/p>
<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
}
, "answeringMemberConstituency" : {"_value" : "Thurrock"}
, "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
, "dateOfAnswer" : {"_value" : "2019-04-04", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-04-04T14:52:55.617Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-03-28", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Skin Cancer: Sunbeds"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the implications for his policies of the 2017 World Health Organization report on sunbeds which found that more than 10,000 melanoma cases each year in the United States of America, Europe and Australia are attributed to sunbed use; and if will make an assessment of the potential merits of making it compulsory for all local authorities to have regulated licensing schemes for sunbed premises.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4056", "label" : {"_value" : "Biography information for Nic Dakin"}
}
, "tablingMemberConstituency" : {"_value" : "Scunthorpe"}
, "tablingMemberPrinted" : [{"_value" : "Nic Dakin"}
], "uin" : "238330"}
, {"_about" : "http://data.parliament.uk/resources/1010758", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1010758/answer", "answerText" : {"_value" : "
As I stated in my previous response, we are giving careful consideration to the potential advantages and disadvantages of the application of the national data opt-out to the National Cancer Patient Experience Survey beyond 2018/19. A decision regarding the application of the national data opt-out to this survey and the Care Quality Commission National Patient Survey will be communicated shortly.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
}
, "answeringMemberConstituency" : {"_value" : "Thurrock"}
, "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
, "dateOfAnswer" : {"_value" : "2018-11-23", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-11-23T11:12:11.393Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-11-20", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cancer"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to Answer of 19 November 2018 to Question 190871 on Cancer, what the potential (a) advantages and (b) disadvantages are of implementing the national data guardian opt-out on the quality of the National Cancer Patient Experience Survey data.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4056", "label" : {"_value" : "Biography information for Nic Dakin"}
}
, "tablingMemberConstituency" : {"_value" : "Scunthorpe"}
, "tablingMemberPrinted" : [{"_value" : "Nic Dakin"}
], "uin" : "193460"}
, {"_about" : "http://data.parliament.uk/resources/1006021", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1006021/answer", "answerText" : {"_value" : "
We are giving full consideration to the potential advantages and disadvantages of the application of the national data opt-out to the national cancer patient experience survey beyond 2018/19, including the quality and completeness of data, and a decision on this will be communicated in due course.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
}
, "answeringMemberConstituency" : {"_value" : "Thurrock"}
, "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
, "dateOfAnswer" : {"_value" : "2018-11-19", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-11-19T17:27:48.077Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-11-13", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cancer"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to Answer of 12 November to Questions 188813 and 188814 on Cancer, what assessment he has made of the potential effect of implementing the national data guardian opt-out on the quality of the National Cancer Patient Experience Survey data.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4056", "label" : {"_value" : "Biography information for Nic Dakin"}
}
, "tablingMemberConstituency" : {"_value" : "Scunthorpe"}
, "tablingMemberPrinted" : [{"_value" : "Nic Dakin"}
], "uin" : "190871"}
, {"_about" : "http://data.parliament.uk/resources/1002675", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1002675/answer", "answerText" : {"_value" : "
We are giving careful consideration to the application of the national data opt-out to the national cancer patient experience survey as stated in the Government\u2019s response to the National Data Guardian Review July 2017 and other national patient experience surveys. This includes looking at the potential advantages and disadvantages of the national data opt-out not applying to these surveys beyond 2018/19.<\/p>
<\/p>
In spring 2018 we confirmed that for 2018/2019 the national data opt-out would not be applied to the national cancer patient experience survey and other patient experience surveys. A decision regarding application of the national data opt-out to these surveys beyond 2018/19 will be communicated in due course.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
}
, "answeringMemberConstituency" : {"_value" : "Thurrock"}
, "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
, "dateOfAnswer" : {"_value" : "2018-11-12", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "188814"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-11-12T15:40:43.827Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-11-06", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cancer"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, when he plans to publish the decision on the future of the National Cancer Patient Experience Survey in relation to the National Data Guardian opt-out beyond 2018.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4056", "label" : {"_value" : "Biography information for Nic Dakin"}
}
, "tablingMemberConstituency" : {"_value" : "Scunthorpe"}
, "tablingMemberPrinted" : [{"_value" : "Nic Dakin"}
], "uin" : "188813"}
, {"_about" : "http://data.parliament.uk/resources/1002676", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1002676/answer", "answerText" : {"_value" : "
We are giving careful consideration to the application of the national data opt-out to the national cancer patient experience survey as stated in the Government\u2019s response to the National Data Guardian Review July 2017 and other national patient experience surveys. This includes looking at the potential advantages and disadvantages of the national data opt-out not applying to these surveys beyond 2018/19.<\/p>
<\/p>
In spring 2018 we confirmed that for 2018/2019 the national data opt-out would not be applied to the national cancer patient experience survey and other patient experience surveys. A decision regarding application of the national data opt-out to these surveys beyond 2018/19 will be communicated in due course.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
}
, "answeringMemberConstituency" : {"_value" : "Thurrock"}
, "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
, "dateOfAnswer" : {"_value" : "2018-11-12", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "188813"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-11-12T15:40:43.883Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-11-06", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cancer"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of enabling the National Cancer Patient Experience Survey to be exemption from the national data guardian opt out after 2018.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4056", "label" : {"_value" : "Biography information for Nic Dakin"}
}
, "tablingMemberConstituency" : {"_value" : "Scunthorpe"}
, "tablingMemberPrinted" : [{"_value" : "Nic Dakin"}
], "uin" : "188814"}
, {"_about" : "http://data.parliament.uk/resources/997543", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/997543/answer", "answerText" : {"_value" : "
Clinical commissioning groups (CCGs) should have regard to the National Institute for Health and Care Excellence (NICE) guideline on the assessment and treatment of people with fertility problems when commissioning services for which they are responsible. This includes the recommendation in the guideline that three cycles of in-vitro fertilisation be offered to qualifying couples where the woman is under the age of 40 and one cycle where the woman is between the ages of 40 and 42.<\/p>
<\/p>
The NICE guideline is evidence based best practice for clinicians but is not mandatory. The availability of National Health Service funded fertility treatment is and always has been a matter for local determination. Decisions on the level of service provision are underpinned by clinical insight and knowledge of local healthcare needs and priorities.<\/p>
<\/p>
NHS England is currently undertaking a project to develop a benchmark price for NHS in-vitro fertilisation. This will help CCGs improve value for money in their commissioning. The Human Fertilisation and Embryology Authority are finalising some good practice advice for CCGs about the commissioning of fertility services, which should help improve the quality of commissioning decisions.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
}
, "answeringMemberConstituency" : {"_value" : "Thurrock"}
, "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
, "dateOfAnswer" : {"_value" : "2018-11-06", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-11-06T11:11:00.473Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-10-30", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Fertility: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department takes to (a) support fertility treatment in the NHS and (b) ensure NHS England and Clinical Commissioning Groups deliver fertility treatments in line with NICE guidelines.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4056", "label" : {"_value" : "Biography information for Nic Dakin"}
}
, "tablingMemberConstituency" : {"_value" : "Scunthorpe"}
, "tablingMemberPrinted" : [{"_value" : "Nic Dakin"}
], "uin" : "185587"}
, {"_about" : "http://data.parliament.uk/resources/914856", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/914856/answer", "answerText" : {"_value" : "
Information about individual clinical commissioning groups\u2019 (CCGs) local commissioning approach to fertility services has never been collected by the Department. NHS England is the national body which has oversight of the functions of the National Health Service commissioning system in England. It is for NHS England to consider what data is necessary for it to undertake this role most effectively, taking account of the burden of data collection on CCGs.<\/p>
<\/p>
Information collected by Fertility Fairness, through Freedom of Information requests, does show a disappointing reduction in the number of CCGs offering the full recommendations of the National Institute for Health and Care Excellence (NICE) Fertility Guidance. The Government has been clear that CCGs should take full account of the NICE Fertility guidelines when considering the assessment and treatment of fertility problems for their local population, as this represents the best evidence of clinical effectiveness.<\/p>
<\/p>
CCGs are accountable to NHS England, which has a key role to ensure that CCGs, as statutory organisations, deliver the best possible services and outcomes for patients within their financial allocation. CCGs have a statutory responsibility to commission services which meet the needs of their local population. CCGs have to make difficult decisions about commissioning cost-effective care, but they do this based on patient needs and clinical evidence. We expect NHS England to ensure the CCG is not breaching its statutory responsibility to provide services that meet the needs of the local population.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
}
, "answeringMemberConstituency" : {"_value" : "Thurrock"}
, "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
, "dateOfAnswer" : {"_value" : "2018-06-11", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "148776"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-06-11T09:55:22.113Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-06-01", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "IVF"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer 21 May 2018 to Questions 144263 and 144264 on In Vitro Fertilisation, for what reason his Department does not collect information on IVF provision centrally; and what assessment he has made of the effect of not holding that information centrally on (a) women seeking IVF and (b) the ability of his Department's to analyse the provision and resourcing of fertility treatment options available in England.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4056", "label" : {"_value" : "Biography information for Nic Dakin"}
}
, "tablingMemberConstituency" : {"_value" : "Scunthorpe"}
, "tablingMemberPrinted" : [{"_value" : "Nic Dakin"}
], "uin" : "148775"}
, {"_about" : "http://data.parliament.uk/resources/914861", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/914861/answer", "answerText" : {"_value" : "
Information about individual clinical commissioning groups\u2019 (CCGs) local commissioning approach to fertility services has never been collected by the Department. NHS England is the national body which has oversight of the functions of the National Health Service commissioning system in England. It is for NHS England to consider what data is necessary for it to undertake this role most effectively, taking account of the burden of data collection on CCGs.<\/p>
<\/p>
Information collected by Fertility Fairness, through Freedom of Information requests, does show a disappointing reduction in the number of CCGs offering the full recommendations of the National Institute for Health and Care Excellence (NICE) Fertility Guidance. The Government has been clear that CCGs should take full account of the NICE Fertility guidelines when considering the assessment and treatment of fertility problems for their local population, as this represents the best evidence of clinical effectiveness.<\/p>
<\/p>
CCGs are accountable to NHS England, which has a key role to ensure that CCGs, as statutory organisations, deliver the best possible services and outcomes for patients within their financial allocation. CCGs have a statutory responsibility to commission services which meet the needs of their local population. CCGs have to make difficult decisions about commissioning cost-effective care, but they do this based on patient needs and clinical evidence. We expect NHS England to ensure the CCG is not breaching its statutory responsibility to provide services that meet the needs of the local population.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
}
, "answeringMemberConstituency" : {"_value" : "Thurrock"}
, "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
, "dateOfAnswer" : {"_value" : "2018-06-11", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "148775"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-06-11T09:55:22.177Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-06-01", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "IVF"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what the implications are for his policies of the recent data for Fertility Fairness on the number of clinical commissioning groups (CCGs) in England offering the recommended three IVF cycles to eligible women under 40 years of age having halved in the last five years and only 12 per cent of all CCGs following national guidance; what assessment he has made of the reasons for that reduction in the number of CCGs offering three cycles and following that guidance; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4056", "label" : {"_value" : "Biography information for Nic Dakin"}
}
, "tablingMemberConstituency" : {"_value" : "Scunthorpe"}
, "tablingMemberPrinted" : [{"_value" : "Nic Dakin"}
], "uin" : "148776"}
, {"_about" : "http://data.parliament.uk/resources/904693", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/904693/answer", "answerText" : {"_value" : "
This information is not collected centrally.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
}
, "answeringMemberConstituency" : {"_value" : "Thurrock"}
, "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
, "dateOfAnswer" : {"_value" : "2018-05-21", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "144264"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-05-21T16:05:40.167Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-05-15", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "IVF"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, how many NHS Trusts in England offered (a) one (b) two (c) three and (d) more than three courses of IVF treatment as a routine service to eligible women in each of the years between 2010 and 2018.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4056", "label" : {"_value" : "Biography information for Nic Dakin"}
}
, "tablingMemberConstituency" : {"_value" : "Scunthorpe"}
, "tablingMemberPrinted" : [{"_value" : "Nic Dakin"}
], "uin" : "144263"}
], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Nic+Dakin&_page=1&answer.answeringMemberConstituency=Thurrock&max-date=2019-05-22", "page" : 0, "startIndex" : 1, "totalResults" : 22, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}